Gemcitabine-Induced Pulmonary Toxicity

Gemcitabine is a pyrimidine analog with a similar chemical structure and mechanism of action, as cytarabine. It has been shown to be a highly active agent for non-small cell lung cancer, pancreatic cancer, urothelial cancer, breast cancer and ovarian cancer. Gemcitabine is relatively well tolerated and myelosuppression is the dose-limiting toxicity. Pulmonary toxicity with gemcitabine is relatively uncommon, but a well recognized entity, associated with significant morbidity and mortality. A high index of suspicion, early diagnosis and timely intervention with oxygen supplementation, steroids, and diuretics is necessary to manage patients with this complication.

[1]  K. Höffken,et al.  Severe non-haematological toxicity after treatment with gemcitabine , 1999, Journal of Cancer Research and Clinical Oncology.

[2]  N. Vander Els,et al.  Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. , 1998, Chest.

[3]  A. Marruchella,et al.  Diffuse alveolar damage in a patient treated with gemcitabine. , 1998, The European respiratory journal.

[4]  N. Pavlakis,et al.  Fatal pulmonary toxicity resulting from treatment with gemcitabine , 1997, Cancer.

[5]  A. Gregor Gemcitabine plus radiotherapy for non-small cell lung cancer. , 1997, Seminars in oncology.

[6]  A. Harris,et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.

[7]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Tarassoff,et al.  950 Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe , 1995 .

[9]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[10]  H. Hansen,et al.  Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Kaye Gemcitabine: current status of phase I and II trials. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Marruchella,et al.  Gemcitabine toxicity. , 1999, Chest.